Voyager Therapeutics (NASDAQ:VYGR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Zacks.com reports.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
VYGR has been the subject of a number of other research reports. Canaccord Genuity restated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Wednesday, January 13th. Cantor Fitzgerald lowered Voyager Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $15.00 to $10.00 in a report on Wednesday, December 23rd. Chardan Capital reduced their target price on Voyager Therapeutics from $15.00 to $6.50 and set a “neutral” rating for the company in a report on Wednesday. BTIG Research lowered Voyager Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday. Finally, Raymond James lowered Voyager Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, December 23rd. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Voyager Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $12.29.
Just $100 in Bitcoin in 2010 would have made you one of the richest people in America with a net worth of over $10 million today. And just recently, Bitcoin kicked off a huge new rally – up as high as 100% in the last two months alone. Now people are pouring into cryptos like we haven’t seen in years… but don’t do anything until you see this new warning.
Shares of NASDAQ:VYGR opened at $7.45 on Friday. Voyager Therapeutics has a one year low of $6.26 and a one year high of $14.62. The stock has a fifty day moving average of $8.14 and a 200-day moving average of $9.99. The company has a market capitalization of $279.12 million, a PE ratio of -4.54 and a beta of 1.80.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Monday, November 9th. The company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $2.46. The company had revenue of $117.84 million during the quarter, compared to the consensus estimate of $43.34 million. Voyager Therapeutics had a negative return on equity of 66.46% and a negative net margin of 60.61%. As a group, research analysts expect that Voyager Therapeutics will post -1.84 earnings per share for the current fiscal year.
In other Voyager Therapeutics news, CFO Allison Dorval sold 2,942 shares of the stock in a transaction on Tuesday, January 12th. The shares were sold at an average price of $8.62, for a total transaction of $25,360.04. Following the transaction, the chief financial officer now directly owns 49,080 shares of the company’s stock, valued at $423,069.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andre Turenne sold 10,443 shares of the stock in a transaction on Tuesday, January 12th. The stock was sold at an average price of $8.62, for a total transaction of $90,018.66. Following the transaction, the chief executive officer now directly owns 156,352 shares in the company, valued at $1,347,754.24. The disclosure for this sale can be found here. 23.90% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Raymond James & Associates grew its position in shares of Voyager Therapeutics by 6.8% in the third quarter. Raymond James & Associates now owns 17,894 shares of the company’s stock valued at $191,000 after purchasing an additional 1,142 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Voyager Therapeutics by 2.6% in the third quarter. California Public Employees Retirement System now owns 58,824 shares of the company’s stock valued at $628,000 after purchasing an additional 1,500 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Voyager Therapeutics by 2.3% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 123,338 shares of the company’s stock valued at $1,316,000 after purchasing an additional 2,783 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Voyager Therapeutics by 87.6% in the third quarter. BNP Paribas Arbitrage SA now owns 6,158 shares of the company’s stock valued at $66,000 after purchasing an additional 2,875 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC grew its position in shares of Voyager Therapeutics by 12.0% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 33,168 shares of the company’s stock valued at $354,000 after purchasing an additional 3,552 shares during the last quarter. 78.79% of the stock is currently owned by hedge funds and other institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson’s disease.
Further Reading: Fundamental Analysis and Individual Investors
Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
10 Cheap Dividend Stocks to Buy Today
While COVID-19 was a sucker-punch to the stock market earlier in the year, the stock market is roaring back. The Dow now over 30,000, and the S&P 500 is trading above 3,700. S&P 500 stocks are trading at nearly 23 times their annual earnings, still well above historical norms.
At the same time, interest rates are near all-time lows (and probably dipping even lower). 10-year Treasuries are yielding just 0.9%, and collectively S&P 500 stocks are yielding under 2%. Some investors think that it’s too challenging to find safe and affordable securities that pay 4%, 5%, and even 6% yields.
Searching for yield isn’t easy in an environment where historically high asset prices and stimulus from the Fed have driven down yields. This doesn’t leave many options for investors looking for retirement income or a decent dividend yield on their stocks, but there are a handful of cheap dividend stocks to buy that are still yielding 3-6%.
Let’s review some of the best cheap dividend stocks in the market today in this slideshow.